Beware ‘Excited’ Non-Healthcare Workers.
As another cohort is now to be offered the antivirals (they are not vaccines), it is apposite to set out some questions to ask those who are falling over themselves to vaccinate you. There is an irony in the fact that reception staff at GPs’ surgeries who are usually obdurate and unable to fit you in for an appointment for weeks are now all so ‘excited’ by these wonderdrugs, despite knowing absolutely nothing about them. One can only presume they are reading from a script and forced to be ‘excited’ for fear of being disciplined. So when a receptionist or volunteer contacts you to offer you a ‘vaccine’, here are some questions to ask them:
The Questions To Ask.
Protective/Sterilising Immunity
BNT126b2; Janssen; mRNA-1273 and Vaxzeria stimulate immunoglobulin G (IgG) only through intramuscular delivery. Therefore none of them can provide protective/sterilising immunity as they bypass the upper respiratory tract and immunoglobulin A stimulation.
Question 1 – Can you confirm that this ‘vaccine’ prevents any subsequent SARS-CoV-2 infection and transmission?
Vitamin D
I have a normal level of vitamin D and functioning vitamin D→eNOS→NO and cholecalciferol→calcifediol→calcitriol pathways. These are highly effective viral countermeasures, in providing both protective/sterilising immunity in the upper respiratory tract – thereby preventing viral infection – and attenuating any disease progression and/or severity.
Question 2 – Can you confirm that this ‘vaccine’ prevents SARS-CoV-2 viral infection and attenuates any COVID-19 disease progression and/or severity more effectively than my own vitamin D pathways?
Antibody-Dependent Enhancement
Gralinski et al.; Ho et al.; Bolles et al. and Tseng et al. show antibody-dependent enhancement (ADE) in coronaviruses in general and sarbecoviruses in particular. Zhao et al.; Gao et al. and Chao et al. show ADE in SARS-CoV-2. ADE was already a proven risk in other sarbecoviruses but in the rushed clinical trials, especially human trials, this was ignored. The ‘vaccines’ being injected stimulate IgG isotype and IgG Fc has a high affinity for FcγRII. There is a positive correlation between polymorphic FcγRIIa/IIb, notably FcγRIIa-R131 and COVID-19 disease severity.
Question 3 – Can you guarantee that this ‘vaccine’ does not under any circumstance cause ADE, particularly if I have inherited polymorphic FcγRII as a result of my ethnic background/ancestry?
Antibody-Dependent Cell-Mediated Cytotoxicity
Chakraborty et al. and Larsen et al. show a relationship between IgG Fc afucosylation and COVID-19 disease severity, in particular acute respiratory distress syndrome (ARDS).
Question 4 – Can you guarantee that this ‘vaccine’ does not under any circumstance cause antibody-dependent cell-mediated cytotoxicity (ADCC), particularly FcγRIII-mediated ADCC triggered by CD56 natural killer cells stimulated by this ‘vaccine’?
Longevity Of Antibodies
Anding et al. show that SARS-CoV-2-specific IgM antibodies are cleared from the humoral system by 56 days following viral clearance and IgG antibodies by 80 days following viral clearance.
Question 5 – For what period do IgG antibodies stimulated by this ‘vaccine’ remain effective in the humoral system?
Effectiveness Against Variants – I
All these ‘vaccines’ assume the structural spike protein is static. They ignore its dynamic glycan shielding and constant changes in the S protein domain through amino acid substitution, single nucleotide polymorphism and insertion/deletion. Garcia-Beltran et al. show both mRNA-1273 and BNT126b2 are effectively useless against the main SARS-CoV-2 variants B1.1.7; B1.1.28 and B1.351.
Question 6 – Can you guarantee that this ‘vaccine’ is able to respond to antigen shift in the spike protein domain, especially the RBD, and is effective against all known and as yet unknown SARS-CoV-2 variants?
Effectiveness Against Variants – II
SARS-CoV-2 variants occur during replication and before seroconversion. Therefore my own immune system will recognise a SARS-CoV-2 variant created during viral infection and will stimulate a variant-specific response.
Question 7 – How will this ‘vaccine’ recognise a future variant acquired through infection or created during viral replication?
Thrombosis Risk
Lipid nanoparticles used in these ‘vaccines’ contain phospholipids as an adjuvant. A common trigger of thrombosis is antiphospholipid syndrome (APS). The phospholipids used in these ‘vaccines’ may be stimulating IgM/IgG isotypes to think healthy cells are infected and cause the self/non-self checkpoint to fail.
Question 8 – Can you guarantee that this ‘vaccine’ does not cause an increased risk of APS, leading to arterial thrombosis?
Anaphylaxis Risk
Both Moderna and Pfizer/BioNTech’s clinical trials were fundamentally flawed: while they found no serious adverse side effects, both sets of clinical trials specifically excluded individuals with any prior history of anaphylaxis caused by polyethylene glycol (PEG). In other words, both companies excluded from their trials the very people most likely to be at most risk. Pfizer/BioNTech also excluded people with a prior history of adverse reaction to any other vaccine. Polyethylene glycol used in mRNA ‘COVID vaccines’ causes a 22-fold increase in anaphylaxis among healthy recipients. PEG has never previously been used in a ‘vaccine’. PEG is contained in both Moderna’s mRNA-1273 and Pfizer/BioNTech’s BNT126b2.
Question 9 – Can you confirm that this ‘vaccine’ poses no increased risk of PEG-triggered anaphylaxis either immediately or in response to any medication containing PEG taken at any time in the future?
Vaccine or Antiviral
An antiviral is given to someone either when they are infected with a virus or immediately preceding likely infection. The sole function of an antiviral is to attenuate the target virus’ infectivity for the here & now, either through reducing any disease severity, reducing the chance of hospitalisation and/or reducing recovery time. Antivirals are therapeutic in nature, working only for a short period of time. A vaccine is given to someone before they are infected with a virus with the objective of providing long-term – ideally lifelong – protection. Vaccines are prophylactic in nature, creating active immunity for the future. Vaccines do not require regular boosters and are unaffected by the phylogenetic evolution of a pathogen, meaning they work against current and future variants.
Question 10 – Is this ‘vaccine’ a vaccine or an antiviral?
As a guide, you should be looking for
- ‘yes’ as the answer to Questions 1-4, 6, 8 & 9;
- ‘at least 10 years’, ideally ‘lifelong’ as the answer to Question 5;
- ‘it won’t’ as the answer to Question 7;
- ‘antiviral’ as the answer to Question 10.
If you are satisfied with the answers to all these questions then consider the antiviral. If you are not, then avoid it.
You are already in possession of a far more effective and safer ‘vaccine’: your own immune system.
